Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...
LOS ANGELES--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, ...
Clinical Trials Arena on MSN
Oric to advance prostate cancer drug to Phase III trials
Despite announcing the prostate cancer drug will advance, Oric’s stock dropped nearly 19%.
A new type of medical treatment is scheduled to travel the highways and byways from headquarters in Temple in an effort to provide treatment to cancer patients, specifically male prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results